The echinocandin micafungin: A review of the pharmacology, spectrum of activity, clinical efficacy and safety

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 8, 2007, Pages 1155-1166

  Wiederhold, Nathan P ^a,b   Lewis II, James S ^b,c  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c University Hospital   (United States)

Author keywords

Aspergillus; Candida; Echinocandin; Invasive aspergillosis; Invasive candidiasis; Micafungin

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; BETA 1,3 GLUCAN; CASPOFUNGIN; CYCLOSPORIN A; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; NIFEDIPINE; PLACEBO; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; RITONAVIR; TACROLIMUS; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ASPERGILLUS; BILIRUBIN BLOOD LEVEL; CANDIDA; CANDIDIASIS; CELL WALL; CHILL; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; ESOPHAGUS CANDIDIASIS; FACE EDEMA; FEVER; FUNGAL CELL; FUNGUS ISOLATION; FUSARIUM; HEART ATRIUM FIBRILLATION; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; INJECTION SITE REACTION; JAPAN; LEUKOPENIA; MACULOPAPULAR RASH; MAMMAL CELL; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYCOSIS; NAUSEA; NEPHROTOXICITY; PANCREATITIS; PHARMACODYNAMICS; PHLEBITIS; PRURITUS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ANALYSIS; THROMBOCYTOPENIA; UNITED STATES; VASODILATATION; VOMITING; ZYGOMYCETES;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; BETA-GLUCANS; CANDIDA; CANDIDIASIS; DRUG INTERACTIONS; DRUG RESISTANCE, FUNGAL; FUNGI; HUMANS; LIPOPROTEINS; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC;

EID: 34250648471     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.8.1155     Document Type: Review

References (90)

1. WISPLINGHOFF H, BISCHOFF T, TALLENT SM et al.: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. (2004) 39(3):309-317.
2. PFALLER MA, DIEKEMA DJ: Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. (2007) 20(1):133-163.
3. ANTONIADOU A, TORRES HA, LEWIS RE et al.: Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (2003) 82(5):309-321.
4. MALANI A, HMOUD J, CHIU L et al.: Candida glabrata fungemia: experience in a tertiary care center. Clin. Infect. Dis. (2005) 41(7):975-981.
5. BODEY GP, MARDANI M, HANNA HA et al.: The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am. J. Med. (2002) 112(5):380-385.
6. PERFECT JR, MARR KA, WALSH TJ et al.: Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. (2003) 36(9):1122-1131.
7. MARR KA, CARTER RA, CRIPPA F, WALD A, COREY L: Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. (2002) 34(7):909-917.
8. WALD A, LEISENRING W, VAN BURIK JA, BOWDEN RA: Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J. Infect. Dis. (1997) 175(6):1459-1466.
9. BADDLEY JW, STROUD TP, SALZMAN D, PAPPAS PG: Invasive mold infections in allogeneic bone marrow transplant recipients. Clin. Infect. Dis. (2001) 32(9):1319-1324.
10. LIN SJ, SCHRANZ J, TEUTSCH SM: Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. (2001) 32(3):358-366.
11. MESSER SA, DIEKEMA DJ, BOYKEN L et al.: Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J. Clin. Microbiol. (2006) 44(2):324-326.
12. PFALLER MA, BOYKEN L, HOLLIS RJ et al.: In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J. Clin. Microbiol. (2005) 43(11):5425-5427.
13. ASTELLAS PHARMA US INC.: Mycamine® (micafungin sodium) for injection prescribing information. Astellas Pharma, US, Inc., Tokyo, Japan (2006).
14. TAWARA S, IKEDA F, MAKI K et al.: In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother. (2000) 44(1):57-62.
15. OLATINWO RO, SCHILDER AM, KRAVCHENKO AN: Incidence and causes of postharvest fruit rot in stored Michigan cranberries. Plant Dis (2004) 88:1277-1282.
16. DEBONO M, GORDEE RS; Antibiotics that inhibit fungal cell wall development. Ann. Rev Microbiol (1994) 48:471-497.
17. PFIZER INC.: ERAXIS™ (anidulafungin) for injection prescribing information. Pfizer Inc., NY, USA (2006).
18. MERCK & CO.: Cancidas® (caspofungin acetate) for injection prescribing information. Merck & Co. NJ, USA (2005).
19. BOWMAN JC, HICKS PS, KURTZ MB et al.: The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob. Agents Chemother. (2002) 46(9):3001-3012.
20. DOUGLAS CM, D'IPPOLITO JA, SHEI GJ et al.: Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob. Agents Chemother. (1997) 41(11):2471-2479.
21. COTA J, CARDEN M, GRAYBILL JR et al.: In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob. Agents Chemother. (2006) 50(11):3926-3928.
22. BEAUVAIS A, BRUNEAU JM, MOL PC et al.: Glucan synthase complex of Aspergillus fumigatus. J. Bacteriol. (2001) 183(7):2273-2279.
23. WATABE E, NAKAI T, MATSUMOTO S, IKEDA F, HATANO K: Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability. Antimicrob. Agents Chemother. (2003) 47(6):1995-1998.
24. KURTZ MB, HEATH IB, MARRINAN J et al.: Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob. Agents Chemother. (1994) 38(7):1480-1489.
25. ARIKAN S, LOZANO-CHIU M, PAETZNICK V, REX JH: In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother. (2001) 45(1):327-330.
26. ARIKAN S, YURDAKUL P, HASCELIK G: Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp. Antimicrob. Agents Chemother. (2003) 47(8):2640-2643.
27. ESPINEL-INGROFF A: In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of die literature. Rev. Iberoam. Micol. (2003) 20(4):121-136.
28. PFALLER MA, BOYKEN L, HOLLIS RJ, et al.: Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. J. Clin. Microbiol. (2006) 44(10):3533-3538.
29. OSTROSKY-ZEICHNER L, REX JH, PAPPAS PG et al.: Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. (2003) 47(10):3149-3154.
30. MORA-DUARTE J, BETTS R, ROTSTEIN C et al.: Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. (2002) 347(25):2020-2029.
31. KUSE ER, CHETCHOTISAKD P, ARNS DA et al.: Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet (2007) Epub ahead of print.
32. OSTROSKY-ZEICHNER L, KONTOYIANNIS D, RAFFALLI J et al.: International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur. J. Clin. Microbiol. Infect. Dis. (2005) 24(10):654-661.
33. HEYN K, TREDUP A, SALVENMOSER S, MULLER FM: Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob. Agents Chemother. (2005) 49(12):5157-5159.
34. NAKAI T, UNO J, IKEDA F et al.: In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob. Agents Chemother. (2003) 47(4):1376-1381.
35. DOMER JE: Monosaccharide and chitin content of cell walls of Histoplasma capsulatum and Blastomyces dermatitidis. J. Bacteriol. (1971) 107(3):870-877.
36. KANETSUNA F, CARBONELL LM: Cell wall composition of the yeastlike and mycelial forms of Blastomyces dermatitidis. J. Bacteriol. (1971) 106(3):946-948.
37. KANETSUNA F, CARBONELL LM, AZUMA I, YAMAMURA Y: Biochemical studies on the thermal dimorphism of Paracoccidioides brasiliensis. J. Bacteriol. (1972) 110(1):208-218.
38. GOODMAN D, PAMER E, JAKUBOWSKI A, MORRIS C, SEPKOWITZ K: Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate. Clin. Infect. Dis. (2002) 35(3):E35-E36.
39. MATSUE K, URYU H, KOSEKI M, ASADA N, TAKEUCHI M: Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin. Infect. Dis. (2006) 42(6):753-757.
40. HAKKI M, STAAB JF, MARR KA: Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob. Agents Chemother. (2006) 50(7):2522-2524.
41. HERNANDEZ S, LOPEZ-RIBOT JL, NAJVAR LK et al.: Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob, Agents Chemother. (2004) 48(4):1382-1383.
42. KROGH-MADSEN M, ARENDRUP MC, HESLET L, KNUDSEN JD: Amphotericin B and caspofungin resistance in Candidaa glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. (2006) 42(7):938-944.
43. LAVERDIERE M, LALONDE RG, BARIL JG et al.: Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother. (2006) 57(4):705-708.
44. MILLER CD, LOMAESTRO BW, PARK S, PERLIN DS: Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy (2006) 26(6):877-880.
45. PELLETIER R, ALARIE I, LAGACE R, WALSH TJ: Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med. Mycol. (2005) 43(6):559-564.
46. MOUDGAL V, LITTLE T, BOIKOV D, VAZQUEZ JA: Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob. Agents Chemother. (2005) 49(2):767-769.
47. BALASHOV SV, PARK S, PERLIN DS: Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob. Agents Chemother. (2006) 50(6):2058-2063.
48. PARK S, KELLY R, KAHN JN et al.: Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. (2005) 49(8):3264-3273.
49. OSHEROV N, MAY GS, ALBERT ND, KONTOYIANNIS DP: Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccbaromyces cerevisiae. Antimicrob. Agents Chemother. (2002) 46(8):2462-2469.
50. WIEDERHOLD NP, KONTOYIANNIS DP, PRINCE RA, LEWIS RE: Attenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob. Agents Chemother. (2005) 49(12):5146-5148.
51. STEVENS DA, ICHINOMIYA M, KOSHI Y, HORIUCHI H: Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob. Agents Chemother. (2006) 50(9):3160-3161.
52. PFALLER MA, BOYKEN L, HOLLIS RJ et al.: In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J. Clin. Microbiol. (2006) 44(3):760-763.
53. ERNST EJ, ROLING EE, PETZOLD CR, KEELE DJ, KLEPSER ME: In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob. Agents Chemother. (2002) 46(12):3846-3853.
54. IKEDA F, WAKAI Y, MATSUMOTO S et al.: Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob. Agents Chemother. (2000) 44(3):614-618.
55. MAESAKI S, HOSSAIN MA, MIYAZAKI Y et al.: Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice. Antimicrob. Agents Chemother. (2000) 44(6):1728-1730.
56. PETRAITIS V, PETRAITIENE R, GROLL AH et al.: Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. (2002) 46(6):1857-1869.
57. GUMBO T, DRUSANO GL, LIU W et al.: Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob. Agents Chemother. (2007) 51(3):968-974.
58. ICHIYASU H, YAMAMURA A, HONDA M et al.: [Successful treatment by voriconazole for pulmonary and adductor magnus muscle aspergillosis induced by immunosuppressive therapy for hypersensitivity pneumonia]. Nihon Kokyuki Gakkai Zasshi (2006) 44(10):754-760.
59. DENNIS CG, GRECO WR, BRUN Y et al.: Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/-mouse model of chronic granutomatous disease. Antimicrob. Agents Chemother. (2006) 50(2):422-427.
60. PETRAITIS V, PETRAITIENE R, SARAFANDI AA et al.: Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J. Infect. Dis. (2003) 187(12):1834-1843.
61. WIEDERHOLD NP, LEWIS RE: The echinocandin antiftingals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin. Investig. Drugs (2003) 12(8):1313-1333.
62. HEBERT MF, SMITH HE, MARBURY TC et al.: Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J. Clin. Pharmacol. (2005) 45(10):1145-1152.
63. HEMENZ J, CAGNONI P, SIMPSON D et al.: Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob. Agents Chemother. (2005) 49(4):1331-1336.
64. HERESI GP, GERSTMANN DR, REED MD et al.: The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr. Infect. Dis. J.(2006) 25(12):1110-1115.
65. CHILLER T, FARROKHSHAD K, BRUMMER E, STEVENS DA: Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus. Antimicrob. Agents Chemother. (2000) 44(12):3302-3305.
66. MOCHIZUKI N, AIBIKI M, MATSUMOTO Y: Evaluation of micafungin activity in serum, including serum synergism. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (27-30 September 2006) M-1598.
67. PADERU P, GARCIA-EFFRON G, BALASHOV S et al.: Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob. Agents Chemother. (2007) Epub ahead of print.
68. WIEDERHOLD NP, NAJVAR LK, BOCANEGRA R et al.: In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob. Agents Chemother. (2007) 51(5):1616-1620.
69. KEIRNS J, SAWAMOTO T, HOLUM M et al.: Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults. Antimicrob. Agents Chemother. (2007) 51(2):787-790.
70. SEIBEL NL, SCHWARTZ C, ARRIETA A et al.: Safety, tolerability and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob. Agents Chemother. (2005) 49(8):3317-3324.
71. LEE JW, SEIBEL NL, AMANTEA M et al.: Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J. Pediatr (1992) 120(6):987-993.
72. WALSH TJ, ADAMSON PC, SEIBEL NL et al.: Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother. (2005) 49(11):4536-4545.
73. WALSH TJ, KARLSSON MO, DRISCOLL T et al.: Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob. Agents Chemother. (2004) 48(6):2166-2172.
74. DE WET N, LLANOS-CUENTAS A, SULEIMAN J et al.: A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin. Infect. Dis. (2004) 39(6):842-849.
75. DE WET NT, BESTER AJ, VILJOEN JJ et al.: A randomized, double blind, comparative trial of micafungin (FK463) versus fluconazole for the treatment of oesophageal candidiasis. Aliment. Pharmacol. Ther. (2005) 21(7):899-907.
76. VILLANUEVA A, GOTUZZO E, ARATHOON EG et al.: A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med. (2002) 113(4):294-299.
77. ARRIETA AC, TELLES FILHO F, BEREZIN E, FREIRE A, DIEKMANN-BERNDT H: A randomized, double-blind trial comparing micafungin and liposomal amphotericin B in pediatric patients with invasive candidiasis. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA (27-30 September 2006) M-1308b.
78. BETTS RF, ROTSTEIN C, TALWAR D et al.: Comparison of micafungin and caspofungin for candidemia or invasive candidiasis. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA (27-30 September 2006) M-1308a.
79. REBOLI A, ROTSTEIN C, PAPPAS P et al.: Anidulahingin versus fluconazole for treatment of candidemia and invasive candidiasis. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington D.C. USA (16-19 December 2005) M-718.
80. REX JH, BENNETT JE, SUGAR AM et al.: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N. Engl. J. Med. (1994) 331(20):1325-1330.
81. REX JH, PAPPAS PG, KARCHMER AW et al.: A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin. Infect. Dis. (2003) 36(10):1221-1228.
82. DENNING DW, MARR KA, LAU WM et al.: Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J. Infect. (2006) 53(5):337-349.
83. MAERTENS J, RAAD I, PETRIKKOS G et al.: Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. (2004) 39(11):1563-1571.
84. GOODMAN JL, WINSTON DJ, GREENFIELD RA et al.: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med. (1992) 326(13):845-851.
85. SLAVIN MA, OSBORNE B, ADAMS R et al.: Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J. Infect. Dis. (1995) 171(6):1545-1552.
86. VAN BURIK JA, RATANATHARATHORN V, STEPAN DE et al.: Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis. (2004) 39(10):1407-1416.
87. SIROHI B, POWLES RL, CHOPRA R et al.: A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant (2006) 38(1):47-51.
88. SAKAEDA T, IWAKI K, KAKUMOTO M et al.: Effect of micafungin on cytochrome, P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J. Pharm. Pharmacol. (2005) 57(6):759-764.
89. HEBERT MF, TOWNSEND RW, AUSTIN S et al.: Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J. Clin. Pharmacol. (2005) 45(8):954-960.
90. HEBERT MF, BLOUGH DK, TOWNSEND RW et al.: Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J. Clin. Pharmacol. (2005) 45(9):1018-1024.